Geburtshilfe Frauenheilkd 2000; 60(1): 41-58
DOI: 10.1055/s-2000-9764
ORIGINALARBEIT

Georg Thieme Verlag Stuttgart · New York

2nd-line-Chemotherapie nach Platin- oder Platin-Paclitaxel-haltiger Primärtherapie beim Ovarialkarzinom: eine systematische Übersicht der publizierten Daten bis 1998

Second-line Chemotherapie after Platinum or Platinum and Paclitaxel-based Chemotherapy for Ovarian Cancer: A Systematic ReviewA. du Bois1 , H. J. Lück2 , T. Bauknecht3
  • 1 Klinik für Gynäkologie und gynäkologische Onkologie, Dr. Horst-Schmidt-Kliniken, Wiesbaden
  • 2 Frauenklinik im Oststadtkrankenhaus, Medizinische Hochschule Hannover
  • 3 Universitäts-Frauenklinik Bonn
  • 4 Universitäts-Frauenklinik Kiel
  • 5 Frauenklinik, ev. Krankenhaus Düsseldorf
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Zusammenfassung

Trotz der in den letzten Jahrzehnten erreichten Fortschritte in der Primärbehandlung des fortgeschrittenen Ovarialkarzinoms erleidet die Mehrzahl der Patientinnen ein Rezidiv der Erkrankung. Die Entwicklung effektiver Rezidivtherapien ist klinisch relevant.

Diese Übersichtsarbeit re-analysiert die bis inklusive 1998 publizierten Daten zur systemischen Chemotherapie (366 Studien mit 13 584 Patientinnen). Hierbei werden die Patientinnenkollektive je nach der Art der Vortherapie (mit oder ohne Platin bzw. Paclitaxel) und dem Ansprechen auf die Vortherapie getrennt analysiert. Bei Letzterem werden Patientinnen mit platinsensiblem Ovarialkarzinom (d. h. Ansprechen auf eine platinhaltige Primärtherapie und Intervall bis zum Auftreten eines Rezidivs von mehr als 6 Monaten) und Patientinnen mit einem platinrefraktären Ovarialkarzinom (d. h. kein Ansprechen auf eine platinhaltige Primärtherapie oder Rezidiv innerhalb von 6 Monaten nach Abschluß der Primärtherapie) getrennt analysiert.

Beim platinsensiblen Ovarialkarzinom werden die besten Ergebnisse mit einer platinhaltigen Re-Induktionstherapie berichtet. Beim platinrefraktären Ovarialkarzinom unterscheiden sich die Ergebnisse verschiedener Chemotherapien nur unwesentlich, eine erneute Platintherapie erscheint wenig sinnvoll. Die Datenlage zu einer 2nd-line-Therapie nach Platin und Paclitaxel, dem aktuellen Standard in der Primärbehandlung ist ungenügend. Lediglich für Topotecan wurde bisher eine (begrenzte) Aktivität in ausreichend großen Studien bewiesen. Leider liegen nur unzureichende Daten aus prospektiv randomisierten Studien vor. Die bisher ungenügenden Therapieergebnisse und der offensichtliche Mangel an validen Daten sollte dazu führen, die 2nd-line-Therapien systematischer im Rahmen kooperativer klinischer Studien zu untersuchen. Die hier vorliegende retrospektive Analyse kann sowohl Hinweise für die Planung zukünftiger Studien geben, als auch helfen, Therapieentscheidung auf dem Boden der zur Verfügung stehenden Daten zu treffen.

Abstract

Purpose: Despite progress in the primary treatment of advanced ovarian cancer, most patients will still develop recurrent disease. We reviewed published studies on systemic second-line chemotherapy for patients with recurrent ovarian cancer.

Material and Methods: We systematically reviewed 366 studies including 13 584 patients published until 1998. Patients were divided into subgroups according to prior treatment (with or without platinum or paclitaxel) and response to prior treatment. Platinum-sensitive disease was defined as responce to platinum and progression-free survival of at least 6 months. Platinum-resistant disease was defined as no responce to platinum or a progression-free interval of less than 6 months after completion of primary treatment.

Results: Patients with platinum-sensitive disease did best after platinum-based reinduction therapy. For platinum-resistant disease there were no differences in response rates among the various published regimens; renewed platinum-based treatment was not effective. There are few data on second-line treatment for patients who have received platinum and paclitaxel. Only topotecan has been shown to have limited activity in adequately large studies. Few data are based on randomized trials.

Conclusions: Disappointing clinical results and a lack of valid data indicate a need for randomized clinical trials. Our data provide a basis for clinicians treating patients with recurrent ovarian cancer and suggest approaches for designing prospective trials.

Literatur

  • 1 McGuire W P, Hoskins W J, Brady M F. et al . Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.  J Engl J Med. 1996;  334 1-6
  • 2 Stuart G, Bertelsen K, Mangioni C. et al . Updated analysis shows highly significant improved overall survival (OS) for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NICIC-CTG and Scottish intergroup trial.  Proc Am Soc Clin Oncol. 1998;  17 1394
  • 3 Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.  J Clin Oncol. 1992;  10 513-514
  • 4 du Bois A, Lück H J, Meerpohl H G. Rezidiv- und 2nd-line Therapien beim Ovarialkarzinom: eine Übersicht konventioneller systemischer Therapiemodalitäten.  Zentrbl Gynäkol. 1997;  119 299-323
  • 5 Kavanagh J J, Tresukosol D, Edwards C. et al . Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.  J Clin Oncol. 1995;  13 1584-1588
  • 6 Ozols R F, Ostchega Y, Curt C, Young R C. High-dose carboplatin in refractory ovarian cancer patients.  J Clin Oncol. 1987;  5 197-201
  • 7 Colombo N, Speyer J L, Green M. et al . Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.  Cancer Chemother Pharmacol. 1989;  23 323-328
  • 8 Williams L L, Fudge M, Burnett L S, Jones H W. Salvage carboplatin therapy for advanced ovarian cancer after first-line treatment with cisplatin.  Am J Clin Oncol. 1992;  15 331-336
  • 9 Eisenhauer E A, Swenerton K D, Sturgeon F G, Fine S, O'Reilly S E. Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Trials Group study.  Cancer Treat Rep. 1986;  70 1195-1198
  • 10 Gore M E, Fryatt I, Wiltshaw E, Dawson T, Robinson B A, Calvert A H. Cisplatin/carboplatin cross-resistance in ovarian cancer.  Br J Cancer. 1989;  60 767-769
  • 11 Repetto L, Chiara S, Mammoliti S. et al . Crossover study with cisplatin or carboplatin in advanced ovarian cancer.  Gynecol Oncol. 1990;  39 146-149
  • 12 Piver M S, Barlow J J, Lele S B, Malfetano J H, McPhee M E. Cis-diamminedichloroplatinum (II): second-line induction chemotherapy in advanced ovarian adenocarcinoma.  J Surg Oncol. 1983;  24 329-331
  • 13 Scotto V, Sbiroli C. Weekly cis-platin as third line chemotherapy in advanced ovarian carcinoma. Phase II study.  Eur J Gynaec Oncol. 1991;  12 51-53
  • 14 Chambers S K, Davis C A, Schwartz P E, Kohorn E I, Chambers J T. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.  Clin Cancer Res. 1996;  2 1693-1697
  • 15 Kjorstad K, Harris A, Bertelsen K. et al . A multicenter phase II study of carboplatin in advanced ovarian carcinoma: final report.  Ann Oncol. 1992;  3 217-222
  • 16 Pohl J, Meerpohl H G, Pfleiderer A. Phase II trial of carboplatin in advanced ovarian cancer.  Cancer Res Clin Oncol. 1988;  114 S53
  • 17 Hoskins P J, O'Reilly S E, Swenerton K D. The „failure free interval” defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing.  Int J Gynecol Cancer. 1991;  1 205-208
  • 18 Calvert A H, Harland S J, Newell D R. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.  Cancer Chemother Pharmacol. 1982;  9 140-147
  • 19 Manetto A, Blessing J A, Hurteau J A. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the Gynecologic Oncology Group.  Gynecol Oncol. 1998;  68 45-46
  • 20 Chambers S K, Davis C A, Chambers J T, Schwartz P E, Lorber M T, Handschumacher R E. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.  Clin Cancer Res. 1996;  2 1699-1704
  • 21 Kavanagh J J, Edwards C L, Freedman R S. et al . A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.  Gynecol Oncol. 1995;  58 106-109
  • 22 Gietema J A, Veldhuis G J, Guchelaar H J. et al . Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.  Br J Cancer. 1995;  71 1302-1307
  • 23 Markman M, De Marco L C, Birkhofer M. et al . Phase II trial of zeniplatin (CL-286 588), a new platinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy.  J Cancer Res Clin Oncol. 1993;  119 234-236
  • 24 Sessa C, Vermorken J, Renard J et al. Phase II study of iproplatin in advanced ovarian carcinoma.  J Clin Oncol. 1988;  6 98-105
  • 25 Weiss G, Green S, Alberts D S. et al . Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.  Eur J Cancer. 1991;  27 135-138
  • 26 Roberts J A, Kudelka A P, Spriggs D R. et al . A phase 2 study of cisplatin analog CI-973 in the treatment of patients with refractory, advanced ovarian cancer.  Int J Gynecol Cancer. 1996;  6 257-260
  • 27 Chollet P, Bensmaine M A, Brienza S. et al . Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.  Ann Oncol. 1996;  7 1065-1070
  • 28 Dieras V, Bounnoux P, Petit T. et al . Oxaliplatin (L-OHP) phase II study in platinum (PT) pretreated advanced ovarian cancer (AOC): preliminary results.  Proc Am Soc Clin Oncol. 1998;  17 364A
  • 29 Soulie P, Bensmaine A, Garrino C. et al . Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.  Eur J Cancer. 1997;  33 1400-1406
  • 30 Piccart-Gebhart M, Green J, Lacave A. et al . Oxaliplatin (L-OHP) phase II study platinum (Pt) pretreated advanced ovarian cancer (AOC): preliminary results.  Proc Am Soc Clin Oncol. 1998;  17 1405
  • 31 Kavanagh J J, Kudelka A P, Gonzales de Leon C. et al . Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.  Clin Cancer Res. 1996;  2 837-842
  • 32 Aapro M, Pujade-Lauraine E, Lhomme C. et al . EORTC Clinical Screening Group phase II study of taxotere in ovarian cancer.  Ann Oncol. 1994;  5 202
  • 33 Francis P, Schneider J, Hann L. et al . Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.  J Clin Oncol. 1994;  12 2301-2308
  • 34 Kaye S B, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer - an updated overview.  Eur J Cancer. 1997;  33 2167-2170
  • 35 Seewaldt V L, Greer B E, Cain J M. et al . Paclitaxel (taxol) treatment for refractory ovarian cancer: phase II clinical trial.  Am J Obstet Gynecol. 1994;  170 1666-1671
  • 36 Trimple E L, Adams J D, Vena D. et al . Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103.  J Clin Oncol. 1993;  11 2405-2410
  • 37 Eisenhauer E A, ten Bokkel Huinink W W, Swenerton K D. et al . European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.  J Clin Oncol. 1994;  12 2654-2666
  • 38 Thigpen J T, Blessing J A, Ball H, Hummel S J, Barrett R J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.  J Clin Oncol. 1994;  12 1748-1753
  • 39 Sarosy G, Stone D A, Rothenberg M. et al . Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.  J Clin Oncol. 1992;  10 1165-1170
  • 40 McGuire W P, Rowinsky E K, Rosenshein N B. et al . Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.  Ann Int Med. 1989;  111 273-279
  • 41 Gore M E, Levy V, Rustin G. et al . Paclitaxel (taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.  Br J Cancer. 1995;  72 1016-1019
  • 42 Sweeten K M, Gershenson D M, Burke T W, Morris M, Levenback C, Silva E G. Salvage chemotherapy for refractory transitional cell carcinoma of the ovary (TTC).   Gynecol Oncol. 1995;  59 211-215
  • 43 Athanassiou A, Pectasides D, Varthalitis I, Dimitriades M, Tsiliakos S, Papazachariou A. Taxol patients with cis/carboplatin-refractory ovarian carcinoma.  Proc Am Soc Clin Oncol. 1994;  13 271
  • 44 ten Bokkel Huinink W, Gore M, Carmichael J. et al . Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.  J Clin Oncol. 1997;  15 2183-2193
  • 45 du Bois A, Lueck H J, Buser K. et al . Extended phase II study of paclitaxel as 3 hour infusion in patients with ovarian cancer previously treated with platinum.  Eur J Cancer. 1997;  33 379-384
  • 46 Markman M, Rose P, Kennedy A. et al . A phase II study of 96 hour paclitaxel (P) as salvage therapy in ovarian carcinoma (OC).  Proc Am Soc Clin Oncol. 1996;  15 283
  • 47 Colombo N, Marzola M, Parma G. et al . Paclitaxel vs. CAP (cyclophosphamide; adriamycin, cisplatin) in recurrent platinum sensitive ovarian cancer: a randomized phase II study.   Proc Am Soc Clin Oncol. 1996;  15 279
  • 48 Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.  Gynecol Oncol. 1996;  64 109-113
  • 49 Tresukol D, Kudelka A P, Gonzales de Leon C. et al . Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer.  Eur J Gynaec Oncol. 1996;  17 188-191
  • 50 Bruzzone M, Catsafados E, Miglietta L. et al . Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.  Oncology. 1996;  53 349-353
  • 51 Andersson H, Horvath G, Mellqvist L, Westberg R. et al . Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot study.  Int J Gynecol Cancer. 1997;  7 262-266
  • 52 Fields A, Hochster H, Runowicz C. et al . SDZ PSC 833/paclitaxel in paclitaxel refractory ovarian carcinoma: a phase II trial with renewed responses.  Proc Am Soc Clin Oncol. 1997;  16 351A
  • 53 Soulie P, Trandafir L, Taama A. et al . Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer.  Anti-Cancer Drugs. 1997;  8 763-766
  • 54 Kuehnle H, Lenaz L, Meerpohl H G. et al . Etoposide in cisplatin-refractory ovarian cancer.  Proc Am Soc Clin Oncol. 1988;  7 527
  • 55 Markman M, Hakes T, Reichman B. et al . Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer.  J Cancer Res Clin Oncol. 1992;  119 55-57
  • 56 Hoskins P J, Swenerton K D. Oral etoposide is active against platinum-resistant epithelial ovarian cancer.  J Clin Oncol. 1994;  12 60-63
  • 57 Kavanagh J J, Tresukosol D, De Leon C G. et al . Phase II study of prolonged oral etoposide in refractory ovarian cancer.  Int J Gynecol Cancer. 1995;  5 351-354
  • 58 de Wit R, van der Burg M EL, v. d. Gaast A, Logmans A, Stoter G, Verweij J. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.  Ann Oncol. 1994;  5 656-657
  • 59 Rose P G, Blessing J A, Mayer A R, Homesly H D. Prolonged oral etoposide as second line therapy for platinum resistant (platr) and platinum sensitive (plats) ovarian carcinoma: a Gynecologic Oncology Group study.  Proc Am Soc Clin Oncol. 1996;  15 282
  • 60 Naumann R W, Alvarez R D, Segars E T. et al . A phase II study of high-dose etoposide as a second-line therapy in patients with epithelial ovarian cancer.  Proc Am Soc Clin Oncol. 1997;  16 364A
  • 61 Kuhn W, Schmalfeldt B, Pache L. et al . Disease-adapted relapse therapy for ovarian cancer: results of a prospective study.  Int J Oncol. 1998;  13 57-63
  • 62 Armstrong D, Rowinsky E, Donehower R, Rosenshein N, Walczak J, McGuire W. A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer.  Proc Am Soc Clin Oncol. 1995;  14 275
  • 63 Rowinsky E K, Grochow L B, Hendricks C B. et al . Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.  J Clin Oncol. 1992;  10 647-656
  • 64 Kudelka A P, Tresukosal D, Edwards C L. et al . Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.  J Clin Oncol. 1996;  14 1552-1557
  • 65 Gordon A, Bookman M, Malmstrom H. et al . Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial.  Proc Am Soc Clin Oncol. 1996;  15 282
  • 66 Creemers G J, Bolis G, Gore M. et al . Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.  J Clin Oncol. 1996;  14 3056-3061
  • 67 Hochster H, Speyer J, Wadler S. et al . Phase II study of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer: a highly active regimen. (a NYGOG study).  Proc Am Soc Clin Oncol. 1996;  15 285
  • 68 Swisher E M, Mutch D G, Rader J S, Elbendary A, Herzog T J. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.  Gynecol Oncol. 1997;  66 349
  • 69 Hoskins P, Eisenhauer E, Beare S. et al . Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.  J Clin Oncol. 1998;  16 2233-2237
  • 70 Bookman M A, Malmström H, Bolis G. et al . Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.  J Clin Oncol. 1998;  16 3345-3352
  • 71 National Institutes of Health Consensus Developement Conference Statement . Ovarian Cancer: screening, treatment, and follow-up.  Gynecol Oncol. 1994;  55 S4-S14
  • 72 Schwartz P E, Keating G, Kohorn E I, Chambers J T. CHAP II therapy for epithelial ovarian cancers following primary treatment with platinum-based combination chemotherapy.   Gynecol Oncol. 1986;  25 340-346
  • 73 Fanning J, Hilgers R D, Hutson E. Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer.  Am J Clin Oncol. 1994;  17 335-337
  • 74 Lorusso V, Catino A, Leone B. et al . Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study.  J Clin Oncol. 1993;  11 1952-1956
  • 75 Lele S B, Piver M S, Malfetano J. Cisplatin plus VP16-213 in refractory ovarian carcinoma.  Am J Clin Oncol. 1987;  10 21-22
  • 76 Baker T R, Piver M S, Hempling R E. The addition of etoposide and ifosfamide to cisplatin as second line therapy in ovarian carcinoma.  Eur J Gynaec Oncol. 1993;  14 18-22
  • 77 Menczer J, Ben-Baruch G, Rizel S, Brenner H. Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma.  Eur J Gynaec Oncol. 1992;  13 316-318
  • 78 Ahmed F Y, King D M, Nicol B. et al . Preliminary results of infusional chemotherapy (cisplatin, epirubicin and 5-fluorouracil, ECF) for refractory and relapsed epithelial ovarian cancer.  Proc Am Soc Clin Oncol. 1995;  14 280
  • 79 ten Bokkel Huinink W W, Dalesio O, Rodenhuis. Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at the Netherlands Cancer Institute.  Sem Oncol. 1992;  19 99-101
  • 80 Beddoe A M, Dottino P R, Cohen C J. Phase II trial of etoposide, carboplatin, and ifosfamide as salvage therapy in advanced ovarian carcinoma.  Mt Sinai J Med. 1993;  60 311-316
  • 81 Dobbs S P, Gribbin C, Chan S Y, Bessel E M. Second-line treatment with ifosfamide and carboplatin in patients with ovarian carcinoma relapsing after treatment with carboplatin.  Eur J Cancer. 1994;  30A 30-33
  • 82 De Lena M, Lorusso V, Bottalico C. Revertant and potentiating activity of lonidamin in patients with ovarian cancer previously treated with platinum.  J Clin Oncol. 1997;  15 3208-3213
  • 83 van der Burg M EL, Logmans A, de Wit R. et al . Six weeks of weekly high-dose cisplatin (P) and daily oral vepesid (VP): a highly active regimen for ovarian cancer patients (PTS) failing on or relapsing after conventional platinum containing combination chemotherapy.  Proc Am Soc Clin Oncol. 1996;  15 285
  • 84 Bower M, Goodchild K, Evans H, Nelstdorf A, Rustin G JS. FaFEC: a novel regimen for advanced ovarian cancer.  Int J Gynecol Cancer. 1997;  7 14-17
  • 85 Johnston C M, Pearl M L, Reynolds R K, Roberts J A, Morley G W. Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single-agent paclitaxel.  Eur J Gynaec Oncol. 1995;  16 439-447
  • 86 Goldberg J M, Piver M S, Hempling R H, Recio F O. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.  Gynecol Oncol. 1996;  63 312-317
  • 87 Guastalla J P, Pujade-Lauraine E, Orfeuvre H. et al . Efficacy and safety of carboplatin (Cb)-paclitaxel (Px) association in pretreated advanced ovarian cancer (AOC) patients (pts).  Proc Am Soc Clin Oncol. 1996;  15 278
  • 88 Kosmas C, Polyzos A, Tsavaris N. et al . Outpatient, taxol (T) ifosfamide (I) and cisplatin (C) (TIP) as salvage chemotherapy in pretreated patients with ovarian cancer (O.C.).  Proc Am Soc Clin Oncol. 1998;  17 366A
  • 89 Guastalla J P, Pujade-Lauraine E, Weber B. et al . Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma.  Ann Oncol. 1998;  9 37-43
  • 90 Sugiyama T, Yakushiji M, Nishida T. et al . Irinotecan (CPT-11) combined with cisplatin on patients with refractory or recurrent ovarian cancer.  Cancer Letters. 1998;  128 211-218
  • 91 Baekelandt M, Covelli A, Trope C, Kristensen G. Phase I/II trial of cisplatin and doxorubicin with SDZ PSC 833 in patients with refractory ovarian cancer.  Proc Am Soc Clin Oncol. 1997;  16 757
  • 92 Bruckner H W, Cagnoni P J, Lee J M, Chesser M R, Andreotti P E. A sequence of adriamycin and taxol infusions for refractory ovarian cancer.  Proc Am Soc Clin Oncol. 1994;  13 271
  • 93 Behrens B, Copeland L, Balcerzak S, Staubus A, Vandre D, Villasmil P. A phase I taxol (T)/altretamine (A) doublet clinical trial in women with refractory ovarian cancer (OC). NCI #T92-0014.  Proc Am Soc Clin Oncol. 1994;  13 271
  • 94 Santoro A, Maiorino L, Santoro M. Taxol (T) plus doxorubicin (D) in platinum (P) pretreated advanced ovarian cancer (A.O.C.) patients (PTS).  Proc Am Soc Clin Oncol. 1996;  15 288
  • 95 Klaassen U, Harstrick A, Stahl M. et al . Paclitaxel and ifosfamide in pretreated patients with advanced ovarian carcinoma - results of a phase I/II study.  Proc Am Soc Clin Oncol. 1996;  15 295
  • 96 Dimopoulos M A, Papadimitriou C, Gennatas C. et al . Ifosfamide and paclitaxel salvage chemotherapie for advanced epithelial ovarian cancer.  Ann Oncol. 1997;  8 195-197
  • 97 Kurbacher C M, Bruckner H W, Cree I A. et al . Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.  Clin Cancer Res. 1997;  3 1527-1533
  • 98 Trope C, Kaern J, Hogberg T. A phase II study of paclitaxel and doxorubicin as second-line treatment in recurrent ovarian cancer after cisplatin failure.  Gynecol Oncol. 1998;  68 123
  • 99 Kurtz J E, Deplanque G, Duclos B. et al . Paclitaxel-anthracycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy: a pilot study.  Gynecol Oncol. 1998;  70 414-417
  • 100 Evans B D, Raju K S, Calvert A H, Harland S J, Wiltshaw E. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.  Cancer Treat Rep. 1983;  67 997-1000
  • 101 Bruckner H W, Wallach R, Cohen C J. et al . High-dose platinum for the treatment of refractory ovarian cancer.  Gynecol Oncol. 1981;  12 64-67
  • 102 Ozols R F, Ostchega Y, Myers C E, Young R C. High-dose cisplatin in hypertonic saline in refractory ovarian cancer.  J Clin Oncol. 1985;  3 1246-1250
  • 103 Barker G H, Wiltshaw E. Use of high-dose cis-dichlorodiammine platinum (II) (NSC-119875) following failure on previous chemotherapy for advanced carcinoma of the ovary.  Br J Obstet Gynaecol. 1981;  88 1192-1199
  • 104 Markman M, Rothman R, Hakes T. et al . Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.  J Clin Oncol. 1991;  9 389-393
  • 105 Gore M E, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.  Cynecol Oncol. 1990;  36 207-211
  • 106 Kehoe S, Redman C, Varma R. et al . Single agent high-dose cisplatin (200 mg/m2) treatment in ovarian carcinoma.  Br J Cancer. 1992;  66 717-719
  • 107 Reed E, Janik J, Bookman M A. et al . High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.  J Clin Oncol. 1993;  11 2118-2126
  • 108 Bolis G, Brusati M, Ferraris A. et al . Carboplatin alone (C) vs. carboplatin + high-dose epirubicin (HDCE) + growth-factors (GF) in late recurrences ovarian cancer patients (PTS).  Proc Am Soc Clin Oncol. 1994;  13 271
  • 109 Conte P F, Gadducci A, Fioretti P, Bruzzone M, Brunetti I, Ragni N. Therapeutic experience of the North-West Oncology Group (GONO) on ovarian carcinoma.  Eur J Gynaec Oncol. 1994;  15 313-318
  • 110 Morgan R J, Margolin K, Raschko J. et al . Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy.  J Clin Oncol. 1995;  13 2238-2246
  • 111 Bolis G, Scarfone G, Luchinin L. et al . Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with cisplatin- or carboplatin-based regimens.  Eur J Cancer. 1994;  30A 1764-1768
  • 112 Dorval T, Soussain C, Beuzeboc P. et al . Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.  J Infus Chemother. 1996;  6 47-49
  • 113 Willemse P HB, Gietema J A, Mulder N H. et al . Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex.  Eur J Cancer. 1993;  29A 359-362
  • 114 Einzig A I, Wiernik P H, Sasloff J, Runowicz C D, Goldberg G L. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.  J Clin Oncol. 1992;  10 1748-1753
  • 115 Kohn E C, Sarosy G, Bicher A. et al . Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.  J Natl Cancer Inst. 1994;  86 18-24
  • 116 Chopra R, Ramesh N, Katiyar C K. A phase I-II study of intaxel, paclitaxel (PCL) obtained from himalayan yew tree (taxus baccata) in advanced ovarian cancer patients (PTS): an Indian experience.  Proc Am Soc Clin Oncol. 1995;  14 280
  • 117 Mendiola C, Garcia-Ribas I, Cubedo R. et al . High response rate of taxol in platinum pretreated advanced ovarian cancer.  Proc Am Soc Clin Oncol. 1995;  14 278
  • 118 Omura G A, Brady M F, Delmore J E. et al . A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study.  Proc Am Soc Clin Oncol. 1996;  15 280
  • 119 Abu-Rustum N R, Aghajanian C, Barakat R R, Fennelly D, Shapiro F, Spriggs D. Salvage weekly paclitaxel in recurrent ovarian cancer.  Sem Oncol. 1997;  24 S15-62-S15-67
  • 120 Fennelly D, Aghajanian C, Shapiro F. et al . Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.  J Clin Oncol. 1997;  15 187-192
  • 121 Ezcurdia L, Jovtis S L, Mickiewicz E. et al . Paclitaxel in platinum-resistant ovarian cancer patients.  Sem Oncol. 1997;  24 (suppl 15) S 15-53, S 15-56
  • 122 Markman M, Rose P G, Jones E. et al . Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.  J Clin Oncol. 1998;  16 1849-1851
  • 123 Pectasides D, Papadopoulou M, Varthalitis J. et al . Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer.  Oncology. 1998;  55 228-234
  • 124 Eckhardt S, Hernadi Z, Thurzo L. et al . Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer.  Oncology. 1990;  47 289-295
  • 125 Hansen F, Malthe I, Krog H. Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer.  Gynecol Oncol. 1990;  36 369-370
  • 126 Hillcoat B L, Campbell J J, Pepperell R, Quinn M A, Bishop J F, Day A. Phase II trial of VP-16-213 in advanced ovarian carcinoma.  Gynecol Oncol. 1985;  22 162-166
  • 127 Seymour M T, Mansi J L, Gallagher C J. et al . Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.  Br J Cancer. 1994;  69 191-195
  • 128 Marzola M, Zucchetti M, Colombo N. et al . Low-dose oral etoposide in epithelial cancer of the ovary.  Ann Oncol. 1993;  4 517-519
  • 129 Kühnle J, Hilfrich J. Chemotherapie des fortgeschrittenen Ovarialkarzinoms.  Onkologie. 1985;  8 374-382
  • 130 Yasumizu T, Kato J. Clinical trial of daily low-dose oral etoposide for patients with residual or recurrent cancer of the ovary or uterus.  J Obstet Gynaecol. 1995;  21 569-576
  • 131 de Jong R S, Hofstra L S, Willemse P HB. et al . Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer.  Gynecol Oncol. 1997;  66 197-201
  • 132 Garrow G C, Hainsworth J D, Johnson D H. et al . Prolonged administration of oral etoposide in previously-treated epithelial ovarian cancer: a phase II trial.  Proc Am Soc Clin Oncol. 1992;  11 236
  • 133 Gore M, Rustin G, Calvert H. et al . A multicentre, randomised, phase III study of topotecan (T) administered intravenously or orally for advanced epithelial ovarian carcinoma.  Proc Am Soc Clin Oncol. 1998;  17 349A
  • 134 Clarke-Pearson D L, Van Le L, Iveson T. et al . A phase II study of oral topotecan as a single agent, second-line therapy, administered for five days in patients with advanced ovarian cancer.  Proc Am Soc Clin Oncol. 1998;  17 363A
  • 135 Eisenhauer E, Hoskins P, Beare S. et al . Randomized phase II study of two schedules of topotecan in previously treated epithelial ovarian cancer (EOC).  Proc Am Soc Clin Oncol. 1997;  16 249A
  • 136 Dunton C J, Neufeld J, Carlson J A. et al . Secondary response of ovarian tumors to topotecan treatment.  Gynecol Oncol. 1998;  69 258-259
  • 137 Ghosh K, Murray K P, Chen M D. et al . The role of extreme drug resistance assays on chemotherapeutic choice and response in ovarian carcinoma patients undergoing secondary cytoreductive surgery.  Gynecol Oncol. 1998;  70 310
  • 138 Veldhuis G J, Willemse P HB, Beijnen J H. et al . Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.  Br J Cancer. 1997;  75 703-709
  • 139 van der Burg M EL, de Wit R, Stoter G, Verweij J. Phase I study of weekly cisplatin (P) and weekly or 4-weekly taxol (T): a highly active regimen in advanced epithelial ovarian cancer (OC).  Proc Am Soc Clin Oncol. 1998;  17 335A
  • 140 Vincent P, Guastalla J P, Piedbois P. et al . Taxol (T) + carboplatin (Cb) combination in pretreated ovarian cancer (OC): a randomized comparison of 2 carboplatin dose calculations (AUC vs. BSA).  Proc Am Soc Clin Oncol. 1998;  17 1453
  • 141 Rose P G, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.  J Clin Oncol. 1998;  16 1494-1497
  • 142 Coeffic D, Benhammouda A, Antoine E C. et al . Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.  Sem Oncol. 1996;  23 5-8
  • 143 van der Burg M EL, Hoff A M, van Lent M, Rodenburg C J, van Putten W LJ, Stoter G. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy.  Eur J Cancer. 1991;  27 248-250
  • 144 Dittrich C, Baur M, Vavra N. et al . Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patients.  Ann Oncol. 1993;  4 697-699
  • 145 Chambers S K, Chambers J T, Kohorn E I, Schwartz P E. et al . Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer.  Gynecol Oncol. 1987;  27 233-240
  • 146 Dottino P R, Goodman H M, Kredentser D, Rosenberg M, Cohen C J. Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma.  Gynecol Oncol. 1987;  27 350-356
  • 147 Seltzer V, Vogl S, Kaplan B. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent.  Gynecol Oncol. 1985;  21 167-176
  • 148 Metzner M, Logue J, Wilkinson P M, James R D. Treatment of relapsed ovarian carcinoma with epirubicin, cis-platinum and 5-fluorouracil (ECF).  Proc Am Soc Clin Oncol. 1995;  14 279
  • 149 Martoni A, Panetta A, Angelelli B, Melotti B, Pannuti F. A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma.  J Chemother. 1993;  5 47-51
  • 150 Gershenson D M, Kavanagh J J, Copeland L J, Stringer C A, Morris M, Wharton J T. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy.  Obstet Gynecol. 1989;  73 798-802
  • 151 Chain J M, Collins C, Petrersdorf S. et al . Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer.  Am J Obstet Gynecol. 1996;  174 1688-1694
  • 152 Bruckner H W, Cohen C J, Bhardwaj S, Feuer E, Chesser M R, Holland J F. Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer.  Eur J Cancer Clin Oncol. 1989;  23 1273-1279
  • 153 Reed E, Sarosy G, Kohn E. et al . Phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary.  Gynecol Oncol. 1996;  61 349-353
  • 154 Olver I N, Davy M. A phase I study of paclitaxel and altretamine in ovarian cancer relapsing after cisplatin.  Proc Am Soc Clin Oncol. 1996;  15 297
  • 155 Pucci F, Bella M, Salvagni S, Passalacqua R, Attolini C, Cocconi G. Paclitaxel and ifosfamide in heavily pretreated patients with advanced ovarian cancer. A pilot fase II study.  Proc Am Soc Clin Oncol. 1996;  15 301
  • 156 Poole C J, Perren T, Hogberg T. et al . Phase I study to investigate the optimal dose and schedule of gemcitabine (G) and paclitaxel (P) in combination in patients with previously treated epithelial ovarian cancer.  Proc Am Soc Clin Oncol. 1998;  17 357A
  • 157 Olver I N, Davy M, Birgeois C. Paclitaxel and altretamine for ovarian cancer relapsing following cisplatin.  Proc Am Soc Clin Oncol. 1998;  17 317A
  • 158 Olver I, Davy M, Webster L, Egorin M, Luftner D, Park S H. A phase I trial with pharmacokinetics of paclitaxel and altretamine for ovarian cancer relapsing following cisplatin.  Ann Oncol. 1998;  9 68
  • 159 Belinson J L, Pretorius R G, McLure M, Ashikaga T. Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies.  Gynecol Oncol. 1986;  23 304-309
  • 160 Sipila P, Kivinen S, Gröhn P, Vesala J, Heinonen E. Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma.  Gynecol Oncol. 1989;  34 27-29
  • 161 Trope C, Kaern J, Vergote I, Vossli S. A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas.  Cancer Chemother Pharmacol. 1990;  26 S45-S47
  • 162 Bruzzone M, Campora E, Merlini L. et al . Ifosfamide and etoposide salvage treatment in advanced ovarian cancer.  J Chemother. 1991;  3 332-334
  • 163 Alberts D, Garcia-Kendall D, Surwit A. Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer.  Sem Oncol. 1988;  15 22-26
  • 164 Barlow J J, Lele S B. Etoposide (VP-16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinoma.  J Surg Oncol. 1986;  32 43-45
  • 165 Redman C, Lawton F, Stuart N. et al . Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer.  Cancer Chemother Pharmacol. 1989;  23 51-53
  • 166 Litam P P, Green J B, Capen C. Mitomycin-C-plus a 4 day continuous infusion of 5-fluorouracil as salvage regimen after platinum-based therapy in women with advanced ovarian cancer and related gynecologic malignancies.  Proc Am Soc Clin Oncol. 1996;  15 288
  • 167 Di Leo A, Bajetta E, Biganzoli L. et al . An I.T.M.O. Group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis.  Eur J Cancer. 1995;  31 2248-2254
  • 168 Marzola M, Parma G, Bonazzi C. et al . Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer.  Ann Oncol. 1996;  7 419-421
  • 169 Nardi M, Della Giulia M, Pollera C F. et al . A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer.  Cancer Chemother Pharmacol. 1996;  38 298-301
  • 170 Fleming G F, Waggoner S E, Rotmensch J, Skoog L A, Langhauser C. Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer.  Gynecol Oncol. 1997;  65 42-45
  • 171 Zanetta G, Lo Monico S, Gabriele A, Miceli D, Mangioni C. Chemotherapie with doxorubicin, etoposide and cyclophosphamide (DEC) in ovarian cancer persistent after platinum-based treatment.  Eur J Cancer. 1996;  32A 178-179
  • 172 Linasmita V, Wilailak S, Srispundit S, Tangtrakul S, Bullangpoti S, Israngura N. Ifosfamide/mesna plus adriamycin as salvage therapy of advanced epithelial ovarian cancer.  Int J Gynecol Cancer. 1997;  7 388-391
  • 173 Herben V MM, ten Bokkel Huinink W W, Dubbelmann A C. et al . Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.  Br J Cancer. 1997;  76 1500-1508
  • 174 Guastalla J P, Ferrero J M, Benbunan J L. et al . Topotecan (T) followed by etoposide (E) in pretreated ovarian cancer (OC) patients (pts): a GINECO phase II study.  Ann Oncol. 1998;  9 67
  • 175 Gwyther S J, Gore M E, ten Bokkel Huinink W. et al . Results of independent radiological review of over 400 patients with advanced ovarian cancer treated with topotecan (Hycamtin).  Proc Am Soc Clin Oncol. 1997;  16 1255
  • 176 Aghajanian C, Gogas H, Fennelly D. et al . Second-line paclitaxel therapy in patients with ovarian cancer previously treated with a taxane.  Proc Am Soc Clin Oncol. 1996;  15 69
  • 177 Schink J C, Narris L S, Grosen E A, Balley H H. Altretamine (hexalen) an effective salvage chemotherapy after paclitaxel (taxol) in women with recurrent platinum resistant ovarian cancer.  Proc Am Soc Clin Oncol. 1995;  14 275
  • 178 Markman M. Ifosfamide in the treatment of ovarian cancer.  Sem Oncol. 1996;  23 47-49
  • 179 Markman M, Kennedy A, Sutton G. et al . Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.  Gynecol Oncol. 1998;  70 272-274
  • 180 Muggia F M, Hainsworth J D, Jeffers S. et al . Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.  J Clin Oncol. 1997;  15 987-993
  • 181 Shapiro J D, Millward M J, Rischin D. et al . Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.  Gynecol Oncol. 1996;  63 89-93
  • 182 Sugiyama T, Nishida T, Ookura N. et al . Is CPT-11 useful as a salvage chemotherapy for recurrent ovarian cancer?.  Proc Am Soc Clin Oncol. 1997;  16 378A
  • 183 de Palo G M, De Lena M, Di Re F, Luciani L, Valagussa P, Bonadonna G. Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary.  Surg Gynecol Obstet. 1975;  141 899-902
  • 184 Gordon A, Carmichael J, Malfetano J. et al . Final analysis of a phase III randomized study of Topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian carcinoma (OC): International Topotecan Study Group.  Proc Am Soc Clin Oncol. 1998;  17 1374
  • 185 Neijt J P, ten Bokkel Huinink W W, van der Burg M EL. et al . Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinoma.  Cancer. 1984;  53 1467-1472
  • 186 Pater J L, Carmichael J A, Krepart G V. et al . Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.  Cancer Treat Rep. 1987;  71 277-281
  • 187 Krafft W. Die Effektivität von Platin als Mono- und Kombinationstherapie bei primär resistentem oder rezidivierendem Ovarialkarzinom.  Zentralbl Gynäkol. 1989;  14 938-946
  • 188 Park R C, Blom J, Disaia P J, Lagasse L D, Blessing J A. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with combination of cytoxan, 5-fluorouracil and dactinomycin.  Cancer. 1980;  45 2529-2542
  • 189 Eisenhauer E A, Vermorken J B, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients.  Ann Oncol. 1997;  8 963-968
  • 190 Hoskins P, Tu D, James K, Koski B. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: A prediction tree analysis-derived model with test and validation groups.  Gynecol Oncol. 1998;  70 224-230
  • 191 Williams C J. Tamoxifen in relapsed ovarian cancer: A systematic review.  Int J Gynecol Cancer. 1998;  8 89-94
  • 192 Kavanagh J J, Roberts W, Townsend P, Hewitt S. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer.  J Clin Oncol. 1989;  7 115-118
  • 193 Miller D S, Brady M F, Barrett R J. A phase II Trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study.  Am J Clin Oncol. 1992;  15 125-128
  • 194 Bruckner H W, Motwani B T. Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue.  Am J Obstet Gynecol. 1989;  161 1216-1218
  • 195 Kurbacher C M, Bruckner H W, Mallmann P, Krebs D. Mitoxantron kombiniert mit Paclitaxel beim platinrefraktären Ovarialkarzinomrezidiv: Präklinische und erste klinische Resultate.  Arch Gynecol Obstet. 1996;  258 S19
  • 196 Eltabbakh G H, Piver M S, Hempling R E. et al . Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.  Gynecol Oncol. 1998;  70 392-397
  • 197 Morgan R J, Speyer J, Doroshow J H. et al . Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.  Gynecol Oncol. 1995;  58 79-85
  • 198 Long III H J, Nelimark R A, Su J Q. et al . Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.  Gynecol Oncol. 1994;  54 180-183
  • 199 de Graeff A, van Hoef M EHM, Tjia P, Heintz A PM, Neijt J P. Continuous infusion of 5-fluorouracil in ovarian cancer patients refractory to cisplatin and carboplatin.  Ann Oncol. 1991;  2 691-692
  • 200 van Oosterom A T, ten Bokkel Huinink W, van der Burg M EL, Vermorken J B, Willemse P HB, Neijt J P. Phase II clinical trial of doxyfluridine in patients with advanced ovarian cancer.  Eur J Cancer. 1991;  27 747-749
  • 201 Louvet C, de Gramont A, Demuynck B. et al . Bi-weekly 2-day schedule of high-dose folinic acid, 5-fluorouracil bolus and infusion in pretreated advanced epithelial ovarian cancer: a phase II study.  Ann Oncol. 1992;  3 657-658
  • 202 Reed E, Jacob J, Ozols R F, Young R C, Allegra C. 5-fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.  Gynecol Oncol. 1992;  46 326-329
  • 203 Look K Y, Muss H B, Blessing J A, Morris M. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma.  Clin Oncol. 1995;  18 19-22
  • 204 Kamphuis J T, Huider M C, Ras G J. et al . High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer.  Cancer Chemother Pharmacol. 1995;  37 190-192
  • 205 Sorensen P, Pfeiffer P, Bertelsen K. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.  Gynecol Oncol. 1995;  56 75-78
  • 206 Markman M, Hakes T, Reichman B. et al . Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.  J Clin Oncol. 1992;  10 243-248
  • 207 Gropp M, Meier W, Hepp H. Treosulfan als effiziente Second-line-Therapie beim Ovarialkarzinom.  Geburtsh u Frauenheilk. 1997;  57 356-360
  • 208 Harstrick A, Wilke H, Eberhard W. et al . A phase I dose escalation trial of intravenous treosulfan in refractory cancer.  Onkologie. 1996;  19 153-156
  • 209 Keldsen N, Madsen E L, Havsteen H. et al . Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study.  Gynecol Oncol. 1998;  69 100-102
  • 210 Hauge M D, Long H J, Hartmann L C, Edmonson J H, Webb M J, Su J. Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer.  Invest New Drugs. 1992;  10 299-301
  • 211 Vergote I, Himmelmann A, Frankendal B, Scheistroen M, Vlachos K, Trope C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.  Gynecol Oncol. 1992;  47 282-286
  • 212 Moore D H, Valea F, Crumpler L S, Fowler W C. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.  Gynecol Oncol. 1993;  51 109-112
  • 213 Vermorken J B, Kobierska A, van der Burg M EL. et al . High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience.  Eur J Gynaec Oncol. 1995;  16 433-438
  • 214 Gaducci A, Brunetti I, Muttini M P. et al . Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer.  Eur J Cancer. 1994;  30A 1432-1435
  • 215 Havsteen H, Bertelsen K, Gadeberg C C. et al . A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer.  Gynecol Oncol. 1996;  63 210-215
  • 216 Safra T, Jeffers S, Groshen S. et al . Doxil (D) in platinum-refractory epithelial ovarian cancer (EOC): results from three consecutive phase I/II studies.  Proc Am Soc Clin Oncol. 1997;  16 349A
  • 217 Garcia A, Muggia F M. Activity of anthracyclines in refractory ovarian cancer: recent experience and review.  Cancer Invest. 1997;  15 329-334
  • 218 Pelaez I, Lacave A J, Palacio I. et al . Phase II trial of epirubicin at standard dose in relapsed ovarian cancer.  Eur J Cancer. 1996;  32A 899-900
  • 219 Locatelli M C, D'Antona A, Vinci M, Carcione R, Pasquinucci C, Luporini G. Trattamento di 2° linea del carcinoma ovarico avanzato (CAO) con epirubicina (EDR).  Tumori. 1997;  76 138
  • 220 Lund B, Hansen O P, Theilade K, Hansen M, Neijt J P. Phase II study of gemcitabine (2'.2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.  J Natl Cancer Inst. 1994;  86 1530-1533
  • 221 Neijt J P, Kaufmann M, Bauknecht T. et al . Gemcitabine in pretreated ovarian cancer.  Ann Oncol. 1996;  7 70
  • 222 George M J, Heron J F, Kerbrat P. et al . Navelbine in advanced ovarian epithelial cancer: a study of the French Oncology Centers.  Sem Oncol. 1989;  16 30-32
  • 223 Bajetta E, Di Leo A, Biganzoli L. et al . Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.  J Clin Oncol. 1996;  14 2546-2551
  • 224 Gershenson D M, Burke T W, Morris M. et al . A phase I study of a daily ×3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.  Gynecol Oncol. 1998;  70 404-409
  • 225 Vergote I B, Trope C G. Ifosfamide-etoposide therapy in platin-resistant ovarian carcinoma.  Proc Am Soc Clin Oncol. 1995;  14 273
  • 226 Look K Y, Blessing J A, Muss H B, DeGeest K. 5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma.  Am J Clin Oncol. 1992;  15 494-496
  • 227 Burnett A F, Barter J F, Potkul R K, Barnes W A. Ineffectiveness of continuous 5-fluorouracil as salvage therapy for ovarian cancer.  Am J Clin Oncol. 1994;  17 490-493
  • 228 Prefontaine M, Donovan J T, Powell J L, Buley L. Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin.  Gynecol Oncol. 1996;  61 249-252
  • 229 Hoffmann L, Koppermann S, Müllerleile U. Treosulfan in the treatment of ovarian carcinoma.  Onkologie. 1991;  14 8-9
  • 230 Kramer D, Golz N, Glaser D, Mast H. Treosulfan als Second-Line-Therapie beim fortgeschrittenen Ovarialkarzinom.  Arch Gynecol Obstet. 1991;  250 195-196
  • 231 Friedlander M, De Gramont A, Millward M J. et al . Activity of gemcitabine in stage 3 or 4 ovarian cancer: patients previously treated with cisplatin (CP)-containing regimens.  Eur J Cancer. 1997;  33 S121-S122
  • 232 Coleman R, Towlson K, Wiltshaw E. et al . Epirubicin for pretreated advanced ovarian cancer.  Eur J Cancer. 1990;  26 850-851
  • 233 Ozols R F, Cunnion R E, Klecker R W. et al . Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.  J Clin Oncol. 1987;  5 641-647
  • 234 Gordon A N, Hainsworth J, Moore M. et al . Doxil (doxorubicin HCl liposome injection) in the treatment of patients with refractory advanced ovarian carcinoma - results of an interim analysis.  Proc Am Soc Clin Oncol. 1998;  17 1345
  • 235 Willemse P HB, van der Burg M EL, van der Gaast A. et al . Ifosfamide given as 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.  Cancer Chemother Pharmacol. 1990;  26 51-54
  • 236 Sutton G P, Blessing J A, Homesley H D, Berman M L, Malfetano J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study.  J Clin Oncol. 1989;  7 1672-1676
  • 237 Rosen G F, Lurain J R, Newton M. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy.  Gynecol Oncol. 1987;  27 173-179
  • 238 Stehman F B, Ehrlich C E, Callangan M F. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.  Gynecol Oncol. 1984;  17 189-195
  • 239 Maneta A, Tewari K, Podczaski E S. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature.  Gynecol Oncol. 1997;  66 20-26
  • 240 Moore D H, Fowler Jr W C, Jones C P, Crumpler L S. Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer.  Am J Obstet Gynecol. 1991;  165 573-576
  • 241 Rustin G JS, Nelstorp A E, Crawford M. et al . Phase II trial of oral altretamine for relapsed ovarian carcinoma: evolution of defining response by serum CA 125.  J Clin Oncol. 1997;  15 172-176
  • 242 Burger R A, Burman S, White R, DiSaia P J. Phase II trial of navelbine in advanced epithelial ovarian cancer.  Proc Am Soc Clin Oncol. 1996;  15 286
  • 243 Rothenberg M L, Ostchega Y, Steinberg S M. et al . High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer.  J Natl Cancer Inst. 1988;  80 1488-1492

PD Dr. med. Andreas du Bois

Klinik für Gynäkologie und gynäkologische Onkologie

Dr.-Horst-Schmidt-Kliniken

Ludwig-Erhard-Straße 100

65199 Wiesbaden

Phone: Tel. 06 11/43 32 03

Fax: Fax 06 11/43 32 05

Email: E-mail: dubois.hsk-wiesbaden@uumail.de